Search Medical Condition
Please enter condition
Please choose location from dropdown

Oral Cavity Cancer Clinical Trials

A listing of Oral Cavity Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (65) clinical trials

Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Arm A: Study Drug Administration: You will receive utomilumab by vein over 60 minutes on Day 1 of each 28-day study cycle. Starting on Day 1 of Cycle 3, you will receive avelumab by vein over 60 minutes on Days 1 and 15 of each cycle after that. You will ...

Phase

Prepare to Care A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

PRIMARY OBJECTIVES: I. To assess feasibility (accrual, participation, and retention) and acceptability of a supported self-management intervention for psycho-education and stress management skills building designed for informal caregivers (n=20) of head and neck cancer (HNC) patients undergoing radiotherapy (RT). II. To obtain preliminary data on caregiver intermediate (self-efficacy for [a] ...

Phase N/A

Carboplatin Nab-Paclitaxel Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

STUDY OBJECTIVES Primary Objective: Estimate the pathologic complete response rate (pCRR) after induction chemotherapy with carboplatin, nab-paclitaxel, and durvalumab in previously untreated stage III and IV SCCHN amenable to surgical resection Secondary Objectives: Report the clinical complete response rate (cCRR) and clinical response rate (cRR) following induction chemotherapy Estimate the ...

Phase

Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you joined the study. Up to 5 groups of 3-6 participants will be enrolled in the dose escalation part of the study. Up to ...

Phase

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Patients with head and neck cancer with high-risk features are at increased risk of relapse after surgery. Surgery, often followed by cisplatin chemotherapy and radiotherapy is currently the standard treatment offered. Whilst chemo-radiotherapy improves cure rates, outcomes remain poor, and treatment has a significant impact on quality of life. Chemotherapy ...

Phase

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

PHASE I: Participants will be enrolled sequentially and treated at Dose Level 1, or Dose Level -1, every 2 weeks for 12 cycles or until discontinuation. Each cycle is 4 weeks. Cetuximab is given alone in lead-in period at Day -14 before Cycle 1 only. In all subsequent doses starting ...

Phase

Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care

PRIMARY OBJECTIVES: I. To assess the diagnostic benefit of the VELscope (direct visual fluorescence) inspection in oral examination. II. Efficacy of the VELscope in identifying dysplastic (premalignant) and malignant oral mucosal lesions and in discriminating these lesions from common benign tissue changes. III. Accuracy of clinical judgment versus VELscope findings. ...

Phase N/A

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Study Drug Administration: There are 28 days in each study cycle. You will receive utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day The drug will be given over about 1 hour each time you receive it. You will receive ISA101b as an ...

Phase

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer

Phase

Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification HER2 Mutation/Amplification or HER3/4 Mutation

Study Groups: Depending on the type of disease and when you join the study, you will receive 1 of 3 drug combinations Group A: Neratinib and Everolimus Group B: Neratinib and Palbociclib Group C: Neratinib and Trametinib Up to 40 participants will be enrolled in each study group. If you ...

Phase